Get the Stockscreener App
1.44
8.86%
-0.14
After Hours:
1.45
0.01
+0.69%
Ventyx Biosciences Inc stock is traded at $1.44, with a volume of 1.17M.
It is down -8.86% in the last 24 hours and down -22.99% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$1.58
Open:
$1.56
24h Volume:
1.17M
Relative Volume:
0.70
Market Cap:
$107.76M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.4364
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
-7.10%
1M Performance:
-22.99%
6M Performance:
-33.94%
1Y Performance:
-83.06%
1-Day Range:
$1.40
$1.58
1-Week Range:
$1.40
$1.615
52-Week Range:
$1.40
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
1.44 | 107.76M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - TipRanks
Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire
Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan
Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks
Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia
Ventyx reports mixed results in Crohn's disease trial - Investing.com India
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 - The Bakersfield Californian
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance
SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
RSLS stock touches 52-week low at $2.57 amid market challenges - MSN
Ventyx Biosciences Inc (NASDAQ: VTYX): Overvalued In Comparison To Others? - Stocks Register
Ventyx Biosciences Inc (VTYX) expanding its growth trajectory ahead - SETE News
Ventyx Biosciences, Inc. (VTYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
VTYX Shares Experience Decline in Value - Knox Daily
Does Ventyx Biosciences Inc (VTYX) offer a good opportunity for investors? - SETE News
Ventyx Biosciences Inc (VTYX) deserves closer scrutiny - US Post News
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Autoimmune Drug Developer Ventyx Takes Center Stage at Major Healthcare Conference - StockTitan
Recent Insider Activity Could Benefit Ventyx Biosciences Inc (VTYX) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Ventyx Biosciences Inc (VTYX)’s Performance - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Sees Large Drop in Short Interest - MarketBeat
Ventyx Biosciences Inc (VTYX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC - Defense World
JPMorgan Chase & Co. Has $2.20 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
What is HC Wainwright’s Estimate for VTYX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat
FY2029 Earnings Estimate for VTYX Issued By HC Wainwright - Defense World
Research Analysts Set Expectations for VTYX FY2029 Earnings - MarketBeat
Ventyx Biosciences Discloses Preliminary 2024 Financials and Pipeline Strategy - Defense World
Ventyx Biosciences highlights its 2025 pipeline strategy - Yahoo Finance
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):